Asymmetric dimethylarginine correlates with measures of disease severity, major adverse cardiovascular events and all-cause mortality in patients with peripheral arterial disease

Vascular Medicine

Volumn 15, Issue 4, 2010, Pages 267-274

  Wilson, Andrew M ^a   Shin, David S ^a   Weatherby, Carlton ^a   Harada, Randall K ^a   Ng, Martin K ^a   Nair, Nandini ^a   Kielstein, Jan ^a   Cooke, John P ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Asymmetric dimethylarginine; Atherosclerosis; Nitric oxide; Peripheral arterial disease; Prognosis

Indexed keywords

N(G),N(G) DIMETHYLARGININE;

ADULT; AGED; ANKLE BRACHIAL INDEX; ARTERY COMPLIANCE; ARTERY DISEASE; ARTICLE; ATHEROSCLEROSIS; BLOOD LEVEL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; SMOKING HABIT; VASCULAR PATENCY;

AGED; AGED, 80 AND OVER; ANKLE BRACHIAL INDEX; ARGININE; BLOOD GLUCOSE; CREATININE; EXERCISE TEST; FEMALE; FOLLOW-UP STUDIES; HUMANS; INSULIN; LIPIDS; MALE; MIDDLE AGED; PERIPHERAL ARTERIAL DISEASE; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 77955904372     PISSN: 1358863X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1358863X10364552     Document Type: Article

References (49)

1. Brevetti G., Oliva G., Silvestro A., Scopacasa F., Chiariello M. Prevalence, risk factors and cardiovascular comorbidity of symptomatic peripheral arterial disease in Italy. Atherosclerosis 2004 ; 175: 131-138.
2. Criqui MH, Vargas V., Denenberg JO, et al. Ethnicity and peripheral arterial disease: The San Diego Population Study. Circulation 2005 ; 112: 2703-2707.
3. Ludmer PL, Selwyn AP, Shook TL, et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 1986 ; 315: 1046-1051.
4. Oemar BS, Tschudi MR, Godoy N., et al. Reduced endothelial nitric oxide synthase expression and production in human atherosclerosis. Circulation 1998 ; 97: 2494-2498.
5. Cooke JP, Singer AH, Tsao P., et al. Antiatherogenic effects of L-arginine in the hypercholesterolemic rabbit. J Clin Invest 1992 ; 90: 1168-1172.
6. Cooke JP NO and angiogenesis. Atheroscler Suppl 2003 ; 4: 53-60.
7. Kuhlencordt PJ, Chen J., Han F., Astern J., Huang PL Genetic deficiency of inducible nitric oxide synthase reduces atherosclerosis and lowers plasma lipid peroxides in apolipoprotein E-knockout mice. Circulation 2001 ; 103: 3099-3104.
8. Cooke JP, Dzau VJ Nitric oxide synthase: Role in the genesis of vascular disease. Annu Rev Med 1997 ; 48: 489-509.
9. Schachinger V., Zeiher AM Atherosclerosis-associated endothelial dysfunction. Z Kardiol 2000 ; 89 (suppl 9). IX / 70-74.
10. Yeboah J., Crouse JR, Hsu FC, Burke GL, Herrington DM Brachial flow-mediated dilation predicts incident cardiovascular events in older adults: The Cardiovascular Health Study. Circulation 2007 ; 115: 2390-2397.
11. Huang AL, Silver AE, Shvenke E., et al. Predictive value of reactive hyperemia for cardiovascular events in patients with peripheral arterial disease undergoing vascular surgery. Arterioscler Thromb Vasc Biol 2007 ; 27: 2113-2119.
12. Cooke JP Asymmetrical dimethylarginine: The Uber marker? Circulation 2004 ; 109: 1813-1818.
13. Dayoub H., Achan V., Adimoolam S., et al. Dimethylarginine dimethylaminohydrolase regulates nitric oxide synthesis: Genetic and physiological evidence. Circulation 2003 ; 108: 3042-3047.
14. Tanaka M., Sydow K., Gunawan F., et al. Dimethylarginine dimethylaminohydrolase overexpression suppresses graft coronary artery disease. Circulation 2005 ; 112: 1549-1556.
15. Konishi H., Sydow K., Cooke JP Dimethylarginine dimethylaminohydrolase (DDAH) promotes endothelial repair after vascular injury. J Am Coll Cardiol 2007 ; 49: 1099-1105.
16. Leiper J., Nandi M., Torondel B., et al. Disruption of methyl-arginine metabolism impairs vascular homeostasis. Nat Med 2007 ; 13: 198-203.
17. Ito A., Tsao PS, Adimoolam S., Kimoto M., Ogawa T., Cooke JP Novel mechanism for endothelial dysfunction: Dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 1999 ; 99: 3092-3095.
18. Stuhlinger MC, Abbasi F., Chu JW, et al. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 2002 ; 287: 1420-1426.
19. Lin KY, Ito A., Asagami T., et al. Impaired nitric oxide synthase pathway in diabetes mellitus: Role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation 2002 ; 106: 987-992.
20. Boger RH, Bode-Boger SM, Szuba A., et al. Asymmetric dimethylarginine (ADMA): A novel risk factor for endothelial dysfunction: Its role in hypercholesterolemia. Circulation 1998 ; 98: 1842-1847.
21. Oka RK, Szuba A., Giacomini JC, Cooke JP A pilot study of L-arginine supplementation on functional capacity in peripheral arterial disease. Vasc Med 2005 ; 10: 265-274.
22. Hiatt WR, Hirsch AT, Regensteiner JG, Brass EP Clinical trials for claudication. Assessment of exercise performance, functional status, and clinical end points. Vascular Clinical Trialists. Circulation 1995 ; 92: 614-621.
23. Fowkes FG The measurement of atherosclerotic peripheral arterial disease in epidemiological surveys. Int J Epidemiol 1988 ; 17: 248-254.
24. McDermott MM, Feinglass J., Slavensky R., Pearce WH The ankle-brachial index as a predictor of survival in patients with peripheral vascular disease. J Gen Intern Med 1994 ; 9: 445-449.
25. Wilson AM, Harada R., Nair N., Balasubramanian N., Cooke JP L-arginine supplementation in peripheral arterial disease: No benefit and possible harm. Circulation 2007 ; 116: 188-195.
26. Wilson AM, O'Neal D., Nelson CL, Prior DL, Best JD, Jenkins AJ Comparison of arterial assessments in low and high vascular disease risk groups. Am J Hypertens 2004 ; 17: 285-291.
27. Corretti MC, Anderson TJ, Benjamin EJ, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: A report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002 ; 39: 257-265.
28. Marzinzig M., Nussler AK, Stadler J., et al. Improved methods to measure end products of nitric oxide in biological fluids: Nitrite, nitrate, and S-nitrosothiols. Nitric Oxide 1997 ; 1: 177-189.
29. Schulze F., Wesemann R., Schwedhelm E., et al. Determination of asymmetric dimethylarginine (ADMA) using a novel ELISA assay. Clin Chem Lab Med 2004 ; 42: 1377-1383.
30. Levey AS, Bosch JP, Lewis JB, Greene T., Rogers N., Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999 ; 130: 461-470.
31. Oka RK, Umoh E., Szuba A., Giacomini JC, Cooke JP Suboptimal intensity of risk factor modification in PAD. Vasc Med 2005 ; 10: 91-96.
32. Hirsch AT, Criqui MH, Treat-Jacobson D., et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001 ; 286: 1317-1324.
33. Kielstein JT, Impraim B., Simmel S., et al. Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation 2004 ; 109: 172-177.
34. Kielstein JT, Donnerstag F., Gasper S., et al. ADMA increases arterial stiffness and decreases cerebral blood flow in humans. Stroke 2006 ; 37: 2024-2029.
35. Savvidou MD, Hingorani AD, Tsikas D., Frolich JC, Vallance P., Nicolaides KH Endothelial dysfunction and raised plasma concentrations of asymmetric dimethylarginine in pregnant women who subsequently develop pre-eclampsia. Lancet 2003 ; 361: 1511-1517.
36. Kielstein JT, Bode-Boger SM, Hesse G., et al. Asymmetrical dimethylarginine in idiopathic pulmonary arterial hypertension. Arterioscler Thromb Vasc Biol 2005 ; 25: 1414-1418.
37. Iribarren C., Husson G., Sydow K., Wang BY, Sidney S., Cooke JP Asymmetric dimethyl-arginine and coronary artery calcification in young adults entering middle age: The CARDIA Study. Eur J Cardiovasc Prev Rehabil 2007 ; 14: 222-229.
38. Miyazaki H., Matsuoka H., Cooke JP, et al. Endogenous nitric oxide synthase inhibitor: A novel marker of atherosclerosis. Circulation 1999 ; 99: 1141-1146.
39. Krzyzanowska K., Mittermayer F., Krugluger W., et al. Asymmetric dimethylarginine is associated with macrovascular disease and total homocysteine in patients with type 2 diabetes. Atherosclerosis 2006 ; 189: 236-240.
40. Boger RH, Bode-Boger SM, Thiele W., Junker W., Alexander K., Frolich JC Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation 1997 ; 95: 2068-2074.
41. Mittermayer F., Krzyzanowska K., Exner M., et al. Asymmetric dimethylarginine predicts major adverse cardiovascular events in patients with advanced peripheral artery disease. Arterioscler Thromb Vasc Biol 2006 ; 26: 2536-2540.
42. Hiatt WR Medical treatment of peripheral arterial disease and claudication. N Engl J Med 2001 ; 344: 1608-1621.
43. Smith I., Franks PJ, Greenhalgh RM, Poulter NR, Powell JT The influence of smoking cessation and hypertriglyceridaemia on the progression of peripheral arterial disease and the onset of critical ischaemia. Eur J Vasc Endovasc Surg 1996 ; 11: 402-408.
44. Creager MA, Gallagher SJ, Girerd XJ, Coleman SM, Dzau VJ, Cooke JP L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. J Clin Invest 1992 ; 90: 1248-1253.
45. Drexler H., Fischell TA, Pinto FJ, et al. Effect of L-arginine on coronary endothelial function in cardiac transplant recipients. Relation to vessel wall morphology. Circulation 1994 ; 89: 1615-1623.
46. Schulman SP, Becker LC, Kass DA, et al. L-arginine therapy in acute myocardial infarction: The Vascular Interaction With Age in Myocardial Infarction (VINTAGE MI) randomized clinical trial. JAMA 2006 ; 295: 58-64.
47. Maas R. Pharmacotherapies and their influence on asymmetric dimethylargine (ADMA). Vasc Med 2005 ; 10 (suppl 1). S49-57.
48. Bae SW, Stuhlinger MC, Yoo HS, et al. Plasma asymmetric dimethylarginine concentrations in newly diagnosed patients with acute myocardial infarction or unstable angina pectoris during two weeks of medical treatment. Am J Cardiol 2005 ; 95: 729-733.
49. Blardi P., de Lalla A., Pieragalli D., et al. Effect of iloprost on plasma asymmetric dimethylarginine and plasma and platelet serotonin in patients with peripheral arterial occlusive disease. Prostaglandins Other Lipid Mediat 2006 ; 80: 175-182.